Photo from wikipedia
Background Information: In early 2018, Children’s Hospital Los Angeles (CHLA) was designated as a Vision Center for treating congenital retinal gene defect (biallelic RPE65 mutationassociated retinal dystrophy) via the injection… Click to show full abstract
Background Information: In early 2018, Children’s Hospital Los Angeles (CHLA) was designated as a Vision Center for treating congenital retinal gene defect (biallelic RPE65 mutationassociated retinal dystrophy) via the injection of Luxturna (gene therapy). CHLA was the first hospital to perform this innovative gene therapy surgery. With innovation comes inherent lack of knowledge, such as aims of the procedure, medication, nursing care, and patient education. An extraordinary amount of preparation and teamwork was required to ensure that the highest level of patient care was delivered to all patients receiving this cutting edge surgical intervention.
Journal Title: Journal of PeriAnesthesia Nursing
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!